Keywords
How to Cite
Abstract
Frequency of separate malignancies and diabetes tends to an increase. This is one of the reasons that diabetes is more often attracting attention as a potential risk factor for cancer. At the same time, in general, relatively less attention is paid to the analysis of the question of whether the presence of diabetes is able to influence on features of neoplasm, inherent at the diagnosis, as well as on the clinical course of the tumor process and its outcomes. In this paper, exactly this aspect of the problem is considered on example of such common and characterized by undoubted specificity of tumors of the female reproductive system as breast cancer and uterine cancer.References
Баранов В.Л., Волкова Е.А.Ворохобина Н.В. и др. Эндокринология, том 2. - СПб.: СпецЛит, 2004. - 432 с.
Берштейн Л.М. Диабет, ожирение и онкологическая заболеваемость: риски и антириски // Сахарный диабет. - 2012. - № 4. - С. 81-88.
Берштейн Л.М. Онкоэндокринология: традиции, современность и перспективы. - СПб.: Наука, 2004. - 343 с.
Берштейн Л.М., Мерабишвили В.М., Карпова И.А. и др. Популяционный анализ сочетания рака и сахарного диабета: частота и особенности // Вопр. онкол. - 2007. - Т. 53. - С. 285-290.
Берштейн Л.М., Цырлина Е.В., Коваленко И.Г. и др. Рецепторный статус опухолей у курящих и страдающих сахарным диабетом больных раком молочной железы // Вопр. онкол. - 2005. - Т. 51. - С. 187-191.
Бохман Я.В. Руководство по онкогинекологии. - Л.: Медицина, 1989. - 464 с.
Дедов И.И., Шестакова М.В. Сахарный диабет (руководство для врачей). - М.: Медицинское информационное агентство, 2011. - 808 с.
Квачевская Ю.О. Особенности рака эндометрия при синдроме инсулинорезистентности: Автореф. дис. канд. мед. наук. - СПб, 2000. - 23 с.
Семиглазов В.Ф., Нургазиев К.Ш., Арзуманов А.С. Опухоли молочной железы (лечение и профилактика). - Алмааты, 2001. - 344 с.
Солун М.Н., Куницына М.А. Сахарный диабет и злокачественные новообразования // Вопр.онкол. - 1987.-Т. 33 (11). - С.7-12.
Attias-Geva Z., Bentov I., Ludwig D.L. et al. Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells // Eur J Cancer. - 2011. - Vol. 47 (11). - P 1717-1726.
Barone B.B., Yeh H.C., Snyder C.F. et al. Long-term allcause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis // JAMA. - 2008. -Vol. 300 (23). - P 2754-2764.
Berstein L.M., Boyarkina M.P., Tsyrlina E.V. et al. More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin // Med Oncol. - 2011. - Vol. 28 (4). - P. 1260-1263.
Campbell P.T., Newton C.C., Patel A.V. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults // Diabetes Care. - 2012. - Vol. 35 (9). - P. 1835-1844.
Chen C, Smothers J, Lange A. et al. Sex hormone-binding globulin genetic variation: associations with type 2 diabetes mellitus and polycystic ovary syndrome // Minerva Endocrinol. - 2010. - Vol. 35 (4). - P 271-280.
Chen H.F., Liu M.D., Chen P. et al. Risks of Breast and Endometrial Cancer in Women with Diabetes: A Population-Based Cohort Study // PLoS one. - 2013. - Vol. 8 (6). - e67420.
Chen W.W., Shao Y.Y., Shau W.Y. The impact of diabetes mellitus on prognosis of early breast cancer in Asia // Oncologist. - 2012. - Vol. 17 (4). - P. 485-491.
Chia V.M., Newcomb А., Trentham-Dietz A., Hampton J.M. Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis // Inter. J. Gyn. Cancer. - 2007. - Vol. 17 (2). - P. 441-446.
Cleveland R.J., North K.E., Stevens J. The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project // Cancer Causes Control. - 2012. - Vol. 23 (7). -P 1193-1203.
Currie C.J., Poole C.D., Evans M. et al. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes // J Clin Endocrinol Metab. - 2013. - Vol. 98 (2). - P 668-677.
De Bruijn K.M., Arends L.R., Hansen B.E. et al. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer // Br. J. Surg. - 2013. - Vol. 100 (11). - P. 1421-1429.
Eliassen A.H., Hankinson S.E. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies // Adv Exp Med Biol. - 2008. - Vol. 630. - P. 148-165.
Ferguson R.D., Gallagher E.J., Cohen D. et al. Hyperin-sulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer // EndocrRelat Cancer. - 2013. - Vol. 20 (3). - Р. 391-401.
Ferguson R.D., Novosyadlyy R., LeRoith D. et al. Hyper-insulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes // Breast Cancer Res. - 2012. - Vol. 14 (1) - R 8.
Fleming S.T, Pursley H.G., Newman B. et al. Comorbidity as a predictor of stage of illness for patients with breast cancer // Med Care. - 2005. - Vol. 43. - P 132-140.
Folsom A.R., Anderson K.E., Sweeney C., Jacobs D.R. Diabetes as a risk factor for death following endometrial cancer // Gynecologic Oncology. - 2004. - Vol. 94 (3). - P. 740-745.
Gallagher E.J., LeRoith D. Minireview: IGF, Insulin, and Cancer // Endocrinology. - 2011. - Vol. 152 (7). - P. 2546-2551.
Giovannucci E., Harlan D.M., Archer M.C. et al. Diabetes and cancer: a consensus report // Diabetes Care. - 2010. - Vol. 33 (7). - P. 1674-1685.
Gliozzo B., Sung C.K., Scalia P. et al. Insulin-stimulated cell growth in insulin receptor substrate-1-deficient ZR-75-1 cells is mediated by a phosphatidylinositol-3-kinase-independent pathway // J Cell Biochem. - 1998. - Vol. 70 (2). - P. 268-280.
Gr ndker C., G nthert A.R., Emons G. Hormonal heterogeneity of endometrial cancer // Adv Exp Med Biol. - 2008. - Vol. 630. - P 166-188.
Guastamacchia E., Resta F., Mangia A. et al. Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets // Curr Drug Targets Immune EndocrMetabolDisord. - 2003. - Vol. 3 (3). - P 205-209.
Liao S., Li J., Wang L. et al. Type 2 diabetes mellitus and characteristics of breast cancer in China // Asian Pac J Cancer Prev. - 2010. - Vol. 11(4). - P933-937.
Mohanraj L, O h Y.Targeting. IGF-I, IGFBPs and IGF-I receptor system in cancer: the current and future in breast cancer therapy // Recent Pat Anticancer Drug Discov. - 2011. - Vol. 6 (2). - P. 166-177.
Mountzios G., Pectasides D., Bournakis E. Developments in the systemic treatment of endometrial cancer // Crit Rev Oncol Hematol. - 2011. - Vol. 79 (3). - P. 278-292.
Nechuta S., Lu W., Zheng Y. et al. Comorbidities and breast cancer survival: a report from the Shanghai Breast Cancer Survival Study // Breast Cancer Res Treat. - 2013. - Vol. 139 (1). - P. 227-235.
Papanas N., Giatromanolaki A., Galazios G. et al. Endometrial carcinoma and diabetes revisited // Eur J Gynaecol Oncol. - 2006. - Vol. 27 (5). -P. 505-508.
Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulinlike growth factors and neoplasia // Nat Rev Cancer. - 2004. - Vol. 4. - P. 505-518.
Rhomberg W. Metastasizing carcinoma of the breast and diabetes mellitus, a prognosticallyfavourable combination // Dtsch Med Wochenschr. - 1975. - Vol. 100 (47). - P. 2422-2427.
Richardson L.C., Pollack L.A. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer // Nat. Clin. Pract.Oncol. - 2005. -Vol. 2 (1). - P. 48-53.
Sanders J.L., Fitzpatrick A.L., Boudreau R.M. et al. Leukocyte telomere length is associated with noninvasively measured age-related disease: The Cardiovascular Health Study // J Gerontol A Biol Sci Med Sci. - 2012. - Vol. 67 (4). - P. 409-416.
Schnell O., Otter W., Standl E. The Munich Myocardial Infarction Registry: translating the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines on diabetes, prediabetes, and cardiovascular disease into clinical practice // Diabetes Care. - 2009. - Vol. 32 - Suppl 2. - P 326-330.
Schveigert D., Cicenas S., Bruzas S. et al. The value of MMP-9 for breast and non-small cell lung cancer patients’ survival // Adv Med Sci. - 2013. - Vol. 58 (1). - P. 73-82.
Sciacca L., Vigneri R., Tumminia A. et al. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients // NutrMetabCardiovasc Dis. - 2013. - Vol. 23 (9). - P. 808-815.
Setiawan V.W., Yang H.P., Pike M.C. et al. Type I and II endometrial cancers: have they different risk factors? // J Clin Oncol. - 2013. - Vol. 31 (20). - P. 2607-2618.
Srokowski T.P., Fang S., Hortobagyi G.N. et al. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer // J ClinOncol. - 2009. - Vol. 27. - P. 2170-2176.
Steiner E., Eicher O., Hofmann M. et al. Endometrial carcinoma in patients with diabetes mellitus // ZentralblGyn-akol. - 2001. - Vol. 123 (11). - P 622-625.
Steiner E., Plata K., Interthal C. Diabetes mellitus is a multivariate independent prognostic factor in endometrial carcinoma: a clinicopathologic study on 313 patients // Eur J GynaecolOncol. - 2007. - Vol. 28 (2). - P. 95-97.
Steiner E., Schmidt M., Weikel W., Koelbl H. Influence of diabetes mellitus and nodal distribution in endometrial cancer and correlation to clinico-pathological prognostic factors // Eur J GynaecolOncol. - 2006. - Vol. 27 (5). - P. 477-480.
Svenson U., Nordfj ll K., Stegmayr B. et al. Breast cancer survival is associated with telomere length in peripheral blood cells // Cancer Res. - 2008. - Vol. 68 (10). - P 3618-3623.
Van de Poll-Franse L.V., Houterman S., Janssen-Heijnen M.L. et al. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis // Int J Cancer. - 2007. - Vol. 120. - P. 1986-1992.
Vigneri P, Frasca F., Sciacca L. et al. Diabetes and cancer // Endocr. Relat.Cancer. - 2009. - Vol. 16 (4). - P 1103-1123.
Wang S., Li W., Liu N. et al. Clinicopathologic characteristics and prognosis for molecular subtypes in low-grade breast carcinoma: comparison with grade one invasive ductal carcinoma-not otherwise specified // Med Oncol. - 2012. - Vol. 29 (4). - P. 2556-2564.
Xihong Z., Douglas Y. Tyrosine kinase signaling in breast cancer: Insulin-like growth factors and their receptors in breast cancer // Breast Cancer Res. - 2000. - Vol. 2 (3). - P 170-175.
Xu J., Chen Y. MYC and Breast Cancer // Genes Cancer. - 2010. - Vol. 1 (6). - P. 629-640.
Zanders M.M., Boll D., van Steenbergen L.N. et al. Effect of diabetes on endometrial cancer recurrence and survival // Maturitas. - 2013. - Vol. 74 (1). - P 37-43.
Zendehdel K., Nyrn O., Ostenson C.G.et al. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden // J Natl Cancer Inst. - 2003. - Vol. 95 (23). - P. 1797-1800.
Zhang J., Lu A., Beech D., Jiang B., Lu Y. Suppression of breast cancer metastasis through the inhibition of VEGF-mediated tumor angiogenesis // Cancer Ther. - 2007. -Vol. 5. - P. 273-286.
Zhang Z.H., Su P.Y., Hao J.H., Sun Y.H. The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies // Int J Gynecol Cancer. - 2013. - Vol. 23 (2). - P. 294-303.
Zhu C., Qi X., Chen Y. et al. PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer // J Cancer Res Clin Oncol. - 2011. - Vol. 137 (11). - P 1587-1594.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2014